1. Home /
  2. Drug Approvals

Drug Approvals

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Jim Cramer Breaks Down the Market and What Could Come Next

Jim Cramer Breaks Down the Market and What Could Come Next

Jim Cramer takes a look at the market.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

What Are the Side Effects of Marijuana? Experts Explain in 2018

What Are the Side Effects of Marijuana? Experts Explain in 2018

As cannabis becomes increasingly legalized in a recreational and medicinal capacity, what actually are the side effects of marijuana? Experts told TheStreet the things you need to know about how the plant affects you.

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

Cannabidiol, or CBD, is a cannabis extract that's used to treat everything from pain to opiate addiction to PTSD. It doesn't get you high -- but advocates say that's the reason that CBD could soon eclipse the multibillion-dollar pot industry.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.